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BMI1 regulates PRC1 architecture and activity
through homo- and hetero-oligomerization
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BMI1 is a core component of the polycomb repressive complex 1 (PRC1) and emerging data
support a role of BMI1 in cancer. The central domain of BMI1 is involved in protein–protein
interactions and is essential for its oncogenic activity. Here, we present the structure of BMI1
bound to the polyhomeotic protein PHC2 illustrating that the central domain of BMI1 adopts
an ubiquitin-like (UBL) fold and binds PHC2 in a b-hairpin conformation. Unexpectedly, we
find that the UBL domain is involved in homo-oligomerization of BMI1. We demonstrate that
both the interaction of BMI1 with polyhomeotic proteins and homo-oligomerization via UBL
domain are necessary for H2A ubiquitination activity of PRC1 and for clonogenic potential of
U2OS cells. Here, we also emphasize need for joint application of NMR spectroscopy and
X-ray crystallography to determine the overall structure of the BMI1–PHC2 complex.
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B
MI1 (B cell-specific Moloney murine leukemia virus
integration site 1) is a polycomb group family
member and emerging data support an important role for
BMI1 in cancer. The gene encoding BMI1 was initially
identified as an oncogene inducing B- and T-cell leukemias1.
Further studies found that BMI1 is a stem cell gene that
determines the proliferative capacity and self-renewal of
normal and leukemic stem cells2. BMI1 is frequently
overexpressed in patients with hematologic3–5 and solid
cancers6–8. Silencing of BMI1 impairs cancer cell proliferation
and tumour growth in cancer models9–15, suggesting that
BMI1 might represent a valid target for therapeutic
intervention16,17.
The mammalian polycomb repressive complex 1 (PRC1) is a
multisubunit protein complex involved in gene silencing18,19.
The canonical PRC1 complex is composed of four core subunits:
CBX (polycomb; CBX2/4/6/7/8), PCGF (polycomb group
factors; PCGF1–6), PHC (polyhomeotic homologues;
PHC1/2/3) and RING E3 ligase (RING1A/B)18,19. The presence
of numerous orthologs results in diverse compositions of
PRC1 with potentially different functions19–21. PRC1 has at
least two distinct activities contributing to repressed gene
transcription: mono-ubiquitination of histone H2A on Lys119
(refs 22,23) and chromatin compaction24,25. The BMI1
protein, also known as PCGF4 (polycomb group RING finger
protein 4), is a central component of the canonical PRC1 complex
and has a dual role in PRC1 activity: regulation of H2A
ubiquitination activity26–28 and mediation of protein–protein
interactions29–33.
BMI1 is a 37 kDa protein composed of three distinct regions:
a N-terminal RING domain26,27, a central domain34 and
a C-terminal proline-serine rich domain involved in the
regulation of protein stability35. The RING domain of BMI1
forms a complex with RING1A/B proteins, which constitutes
the heterodimeric E3 ubiquitin ligase subunit of the PRC1
complex26,27. BMI1 itself has no ubiquitin ligase activity but
through a direct interaction it stabilizes RING1A/B, leading
to increased H2A ubiquitination activity26,28. The central domain
of BMI1 was initially predicted as a putative helix-turn-helix
(HTH) domain36 and more recently was defined as an
ubiquitin-like (UBL) domain, also called RAWUL (RING
finger- and WD40-associated ubiquitin-like) domain34. This
domain is involved in protein–protein interactions and its best
characterized binding partners are the polyhomeotic proteins
(PHC1, PHC2, PHC3)29,30. In addition to interactions within
PRC1, the BMI1 central domain has also been implicated in other
protein–protein interactions, including the transcription factors
E4F1 (ref. 31), Zfp277 (ref. 32) and the PLZF-RARA fusion
protein33.
Functional studies revealed that the central domain of BMI1 is
essential for its oncogenic activity. Deletion analysis shows
that this domain is necessary for transcriptional repression
activity36, immortalization of mammary epithelial cells37 and
lifespan extension of human fibroblasts38. However, the structure
and molecular mechanisms determining how the central
domain of BMI1 contributes to the overall architecture and
function of the canonical PRC1 complex have not been
fully elucidated. To address these questions we determined
the three-dimensional structure of the PHC2–BMI1 complex
revealing that the BMI1 central domain adopts an ubiquitin-like
(UBL) fold and binds a short, 24 amino acid fragment of
PHC2 in a b-hairpin conformation. Unexpectedly, we find
that the UBL domain is involved in homo-oligomerization
of BMI1. Our work reveals that both hetero- and homo-
oligomerization of the UBL domain contribute to BMI1
function and activity.
Results
The BMI1 central domain binds directly to the PHC2 HD1.
The central domain of BMI1 has been reported to interact
with the polyhomeotic PHC2 protein and we sought
to characterize the molecular details of this interaction
(Fig. 1a)29,30. To confirm a direct interaction between BMI1 and
PHC2 we developed a cellular pulldown assay overexpressing an
Avi-tagged BMI1 construct lacking the N-terminal RING domain
(Avi-BMI1106–326) and a Myc-tagged full-length short isoform
of PHC2 (PHC2_B). Streptavidin pulldown of biotinylated
Avi-BMI1106–326 demonstrates that the fragment of BMI1
lacking the RING domain interacts with Myc-PHC2 (Fig. 1b).
Further co-immunoprecipitation experiments confirmed the
interaction of full length BMI1 with PHC2 (Supplementary
Fig. 1a) and showed slightly less efficient binding with full length
BMI1 when compared to BMI1106-326 (Supplementary Fig. 1b).
To define the central domain within BMI1 that binds PHC2 and
is suitable for structural studies we employed bioinformatic
analysis and selected a construct encompassing BMI1 residues
106–240. While the 1H–15N HSQC spectrum for this construct is
consistent with a folded domain, it is not optimal for structural
studies due to the presence of a significant number of disordered
residues (Fig. 1c, top). To define the boundaries of the
globular central domain we employed carbon detected NMR
experiments to efficiently identify flexible regions. We assigned
disordered fragments in BMI1106-240 by employing a combination
of 13C-detected 2D CACO, CBCACO and CANCO experiments
using a previously published protocol39. We identified residues
106–120 and 236–240 as being highly flexible in solution
(Supplementary Fig. 2). Deletion of these residues significantly
improved the quality of 1H–15N HSQC spectra yielding a central
domain construct BMI1121–235 suitable for structural studies
(Fig. 1c, bottom).
Previous studies found that in cells the homology domain 1
(HD1) of PHC2 mediates the interaction with BMI1 (refs 30,40).
To validate the interaction of PHC2 HD1 (residues 1–79) with
the central domain of BMI1 and assess the binding affinity we
employed isothermal titration calorimetry (ITC). We found that
PHC21–79 binds to BMI1121–235 with sub-micromolar affinity
(KD¼ 398 nM) and 1:1 stoichiometry (Fig. 1d). These results
validate a direct interaction between the HD1 domain of PHC2
and the central domain of BMI1.
BMI1 recognizes a short fragment of PHC2. To map PHC2
residues involved in binding to BMI1 we employed NMR. We
found that PHC21–79 is disordered in solution as judged by poor
peak dispersion on the 1H–15N HSQC spectra (Supplementary
Fig. 3). To identify the minimal motif of PHC2 required for
binding to BMI1, we again employed the carbon-detected NMR
experiments. We titrated 13C,15N PHC21–79 with unlabelled
BMI1 and found strong broadening for a subset of resonances on
2D CACO and CBCACO spectra (Fig. 1e). This indicated that a
shorter fragment of PHC21-79 is involved in binding to BMI1, and
to identify these residues we assigned backbone chemical shifts in
PHC21-79 using CACO, CBCACO and CANCO experiments.
We found that the most significantly perturbed signals
correspond to PHC2 residues 33–59 indicating that this
represents the BMI1-binding motif in the PHC2 (Fig. 1f). To
validate this finding we tested the binding of PHC2 fragments
using ITC and found that PHC233-56 binds to BMI1 with a
similar affinity as PHC21–79 (KD¼ 413 nM) (Supplementary
Fig. 4). Furthermore, deletion of residues 30–51 from full
length PHC2 abolished the interaction with BMI1106–326 and full
length BMI1 in pull-down experiments performed in HEK293
cells (Fig. 1a, Supplementary Fig. 1a), further supporting that this
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region is important for binding. Overall, we concluded that a
relatively short, 24 amino acid fragment of PHC2 (PHC233–56)
represents the BMI1 binding motif. This motif is strongly
conserved between PHC2, PHC1 and PHC3 suggesting that
BMI1 interacts with the three members of the polyhomeotic
family (Fig. 1f) in a very similar manner and with similar
affinities.
Structure determination using joint X-ray and NMR refinement.
To understand the molecular basis of the BMI1–PHC2
interaction we pursued structural studies. We obtained crystals
of BMI1121–235 co-crystalized in the presence of the PHC233–56
fragment, which diffracted to 2.5 Å resolution (Table 1). To
determine the crystal structure we used molecular replacement
using a structural model derived from the BMI1 homolog PCGF1,
with 31% sequence identity to BMI1 (ref. 41) (Table 1).
The structure confirmed that the central domain of BMI1 adopts
an ubiquitin-like (UBL) fold (Fig. 2a). While we could refine
the structure of the UBL domain we were not able to model
the PHC2 fragment into the remaining electron density.
The unmodelled electron density was found in a wide
opening between the b2 strand and a1 helix at the interface
between the two BMI1 UBL symmetry related molecules (Fig. 2a,
Supplementary Fig. 5). The incomplete model of the complex is
reflected by relatively high R-factor values (Table 1).
To determine the complete structure of the BMI1–PHC2
complex we turned to solution NMR. Due to limited solubility
and stability of the BMI1–PHC2 complex we made a fusion
protein connecting PHC230–64 fragment fused to the N-terminus
of the BMI1 UBL domain. This construct was designed to include
the intact BMI1 interacting motif in PHC2 as well as a short, 8
amino acid linker to ensure proper folding of the complex.
The HSQC spectrum of the fusion protein was nearly identical to
the spectrum of 15N BMI1 UBL saturated with unlabelled
PHC232–61, demonstrating that the fusion protein recapitulates
the structure of the non-covalent complex (Supplementary
Fig. 6). We noted significant broadening of PHC2–BMI1
resonances at concentrations above 200mM, which precluded
complete chemical shift assignment and determination of the
PHC2–BMI1 structure solely based on the NMR data. However,




























































































































Figure 1 | Mapping of the BMI1–PHC2 interaction. (a) Schematics of the domain structures of BMI1 and PHC2. Dashed lines connect the interacting UBL
and HD1 domains. (b) Streptavidin pull-down in HEK293 cells transfected with Avi-tagged wild-type BMI1 fragment 106–326 or R165E, H174E double
mutant, BirA and Myc-tagged wild-type PHC2_B or PHC2_B with deleted residues 30–51. Western blots are probed as indicated. (c) Optimization of BMI1
constructs for structural studies: (top) 1H–15N HSQC spectrum of BMI1106–240; (bottom)
1H–15N HSQC spectrum of BMI1121-235. (d) Characterization of the
affinity and stoichiometry of the BMI1–PHC21–79 interaction using isothermal titration calorimetry with BMI1121–235 titrated with PHC21–79. (e) Superposition
of CACO spectra for 60mM PHC21–79 (red) and 60mM PHC21–79 with equimolar concentration of unlabelled BMI1121–235 (black). PHC2 residues broadened
in the presence of BMI1 are labelled. (f) Sequence alignment of the three human PHC proteins. Residues of PHC2_B that are perturbed on addition of
BMI1121–235 are shown in red.
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assignment for PHC2–BMI1 and assigned a significant number
of intra-PHC2 and PHC2–BMI1 NOEs. To determine the
structure of the PHC2–BMI1 complex we integrated the
crystal structure of the UBL domain and NMR restraints for
intramolecular PHC2 and intermolecular PHC2–BMI1 contacts.
The initial structure of PHC2–BMI1 was calculated in CYANA42
followed by refinement using the Rosetta software incorporating
both X-ray crystallography and NMR data43,44. The structure of
the UBL domain was constrained during the refinement with
the exception of side chains of residues 160–178 at the interface
with PHC2 (Table 2). Joint refinement using the crystal structure
of the BMI1 UBL domain and NMR distance restraints for
PHC2 was necessary to determine the overall structure of the
PHC2–BMI1 complex (Fig. 2b).
The UBL domain binds PHC2 motif in b-hairpin conformation.
The structure of the PHC2–BMI1 complex shows that PHC2 binds
into a hydrophobic site between the a1 helix and b2 strand
(Fig. 2c). PHC2 residues 33–47 are well structured and adopt a
b-hairpin conformation in the complex (Fig. 2c). The PHC2–BMI1
interaction involves an antiparallel b-sheet formed between the
b-hairpin of PHC2 and the b2 strand of BMI1 UBL, which is
stabilized by the hydrogen bonds between BMI1 Tyr163 and PHC2
Gly46. The PHC2 b-hairpin buries the hydrophobic side chains of
Ile38, Phe41 and Ile43 which pack onto the hydrophobic BMI1
interface lined with residues Leu164, Cys166, Pro167, Met170,
Leu175 and Phe178 (Fig. 2d). Notably, PHC2 Glu45 is buried at
the interface and makes electrostatic contacts with BMI1 Arg162
and Lys182 (Fig. 2d). Mapping of PHC2 by 13C detected NMR
experiments revealed that a longer fragment (PHC233–56) is
involved in binding to BMI1. Based on the structure of
PHC2–BMI1 we determined that PHC2 residues 48–56 are not
well ordered in the structure, as supported by the random coil
chemical shifts and lack of long range NOEs. It is likely that these
residues are involved in long range electrostatic interactions
stabilizing the PHC2–BMI1 complex (for example, the interaction
of PHC2 Glu48 with BMI1 Arg165).
Superposition of the PHC2–BMI1 structure with the crystal
structure of BMI1 UBL shows that the PHC2 fragment overlaps
with the unmodelled electron density observed in the crystal
(Supplementary Fig. 7). Since PHC2 binds at the interface of two
symmetry related BMI1 UBL molecules, most likely in the crystal
structure one molecule of PHC2 is bound to each monomer with
50% occupancy. This unusual binding stoichiometry observed in
the crystal structure precludes modelling of the complex solely
based on the X-ray data.
Point mutations in BMI1 disrupt the interaction with PHC2.
We used the structure of the PHC2–BMI1 complex to design
mutations in BMI1 disrupting the interaction with PHC2. We
rationalized that mutation of Arg165 and His174 in BMI1 to
glutamic acids would introduce a significant electrostatic
repulsion with PHC2 Glu48 and Glu39, respectively. We tested
binding of these mutants to fluorescein-tagged PHC232–61 using a
fluorescence polarization assay (Fig. 2e). While wild-type BMI1
UBL binds PHC232–61 with KD¼ 0.215±0.016 mM, both
BMI1 mutants showed substantially reduced binding affinities.
The R165E mutation reduced the binding affinity by B30-fold
(KD¼ 5.9±0.9 mM) and the H174E mutation resulted in a
100-fold loss in the binding affinity (KD¼ 20.13±2.8 mM).
Introduction of the double R165E/H174E mutation into BMI1
nearly completely abolished the interaction with PHC2
(KD450mM). NMR analysis of the BMI1 UBL domain mutants
revealed that these mutants remain folded in solution
(Supplementary Fig. 8a) and confirmed that the R165E/H174E
double mutant had significantly reduced binding to PHC2
(Supplementary Fig. 8b). To further validate that point mutations
in BMI1 impair binding to PHC2 we performed pull-down
experiments in HEK293 cells and found that the BMI1
R165E/H174E mutant does not associate with PHC2 (Fig. 1b,
Supplementary Fig. 1). To further probe whether hydrophobic
contacts contribute to the BMI1–PHC2 interaction we introduced
M170E point mutation in BMI1 and found that it significantly
reduced the binding to PHC2 by B80-fold (KD¼ 17±1.7 mM)
(Supplementary Fig. 8c).
BMI1 UBL forms higher order oligomers in solution. We
observed that the NMR spectra of all tested BMI1 constructs
showed a concentration-dependent peak broadening consistent
with protein self-association in solution. Importantly, the
self-association of BMI1 was not affected by the presence of
PHC2 suggesting that oligomerization may represent an intrinsic
property of the BMI1 UBL domain. To characterize the
oligomerization of the BMI1 UBL domain we employed analytical
ultracentrifugation experiments45. We found a concentration
dependent increase in sedimentation coefficients for the BMI1
UBL–PHC21–79 complex (Fig. 3a). Although we were not able to
determine quantitatively the population of oligomers, these data
are consistent with the propensity of the BMI1–PHC2 complex to
form higher order oligomers in solution.
To investigate potential oligomerization interfaces we inspected
the crystal packing of the UBL domain in the structure of the
BMI1–PHC2 complex. Analysis of the crystal packing using PISA
software46 suggests two possible homo-oligomerization interfaces
(Fig. 3b). The first interface is predominantly hydrophobic and
comprises residues D184–F189 and Y225–T230 and has a buried
surface area of 462Å2 with predicted DG¼  10.4 kcalmol 1
for the association energy. The second interface is centered
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BMI1, B cell-specific Moloney murine leukemia virus integration site 1; UBL, ubiquitin like.
*Values in parentheses are for highest-resolution shell.
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around Ile212 and involves a cluster of tyrosine side chains
(Tyr202, Tyr203, Tyr211 and Tyr213) that form a hydrogen
bond network with backbone carbonyls. This interface is
smaller, with 398Å2 buried surface area and with a predicted
DG¼  2.4 kcalmol 1 for the association energy. To probe
these two potential oligomerization interfaces we designed two
point mutations: F189Q and I212E with the goal to disrupt
hydrophobic contacts. The 1H–15N HSQC spectra demonstrate
that both mutants are folded in solution (Supplementary Fig. 9a)
and FP measurements indicate that these mutations do not
substantially affect PHC2 binding to BMI1 (KD¼ 0.409±0.16 mM
for F189Q BMI1 mutant and KD¼ 1.04±0.25 mM for
I212E BMI1 mutant) (Fig. 3c). We also validated by NMR
and co-immunoprecipitation that the I212E mutant binds PHC2
in a similar manner as the wild-type protein (Supplementary
Figs 1 and 9a). To assess whether these point mutations
affect the propensity of BMI1 UBL to homo-oligomerize we
again employed analytical ultracentrifugation (Fig. 3d).
Sedimentation velocity experiments showed that the BMI1 UBL
F189Q–PHC21-79 complex has concentration dependent
sedimentation coefficients similar to the wild-type protein,
indicating that this mutant is still able to form higher order
oligomers. Interestingly, the sedimentation coefficients of the
I212E mutant did not show such concentration dependence
(Fig. 3d). This indicates that the I212E mutant has a reduced
tendency for oligomerization supporting the second interface as a
homo-oligomerization interface of BMI1.
We further used NMR to assess whether the I212E mutation
blocks the concentration dependent broadening of NMR spectra
for the BMI1–PHC2 complex. For this purpose, we titrated 15N
labelled BMI1–PHC2 complex with either unlabelled wild-type or
BMI1 I212E–PHC2 complex. As expected, addition of 100mM
unlabelled wild-type BMI1–PHC2 complex resulted in significant
broadening of the resonances on the HSQC spectrum of 50mM
15N BMI1–PHC2 (Fig. 3e, Supplementary Fig. 9c,d). On the
contrary, addition of 100mM unlabelled BMI1 I212E–PHC2
complex did not cause peak broadening (Fig. 3f, Supplementary
Fig. 9c,d). Altogether, both NMR and analytical ultracentrifugation
experiments consistently validate that mutation of Ile212 impairs
homo-oligomerization of the BMI1–PHC2 complex.
BMI1–PHC2 and BMI1–BMI1 interactions regulate PRC1 activity.
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Figure 2 | Structure of the PHC2–BMI1 complex. (a) Crystal structure of the BMI1 UBL domain with Fo-Fc electron density map showing unmodelled
density (blue). (b) Ten lowest energy structures of the PHC2–BMI1 complex determined using joint refinement employing NMR and X-ray data. The
backbone of BMI1 residues 130–231 is shown in green and PHC2 residues 31–50 are shown in blue. Unstructured residues are omitted for clarity.
(c) The overall structure of the PHC2–BMI1 complex using ribbon representation. Side chains of residues mutated to disrupt the PHC2–BMI1 interaction are
shown in sticks. (d) Details of the PHC2–BMI1 interface. (e) Binding affinities of PHC2 with BMI1 variants determined using fluorescence polarization (FP)
experiments titrating FITC–PHC232–61 with wild-type BMI1 UBL or point mutants. Experiments were performed in duplicates, error bars represent s.d.; KD is
reported as an average and s.d. from three independent experiments.
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for histone H2A, a mark associated with repressed gene
transcription22,23. We sought to evaluate whether point
mutations in the UBL domain that impair either the
interactions with PHC2 or BMI1 homo-oligomerization affect
the level of H2A ubiquitination. First, we determined the effect of
BMI1 knockdown on the level of histone H2A Lys119
ubiquitination (Ub-H2A) in HeLa cells. We found reduced Ub-
H2A levels on BMI1 knockdown (Fig. 4a), in agreement with the
previous report47. We next assessed whether overexpression of
either wild-type BMI1 or point mutants can rescue H2A
ubiquitination observed on BMI1 knockdown. HeLa cells
transfected with BMI1 small interfering RNA (siRNA) were
subsequently transfected with BMI1 variants and the level of Ub-
H2A was analysed by immunoblotting (Fig. 4b, Supplementary
Fig. 10). Overexpression of wild-type BMI1 significantly increased
Ub-H2A levels, while overexpression of the R165E/H174E or
I212E mutants failed to rescue Ub-H2A levels (Fig. 4b,
Supplementary Fig. 10). Interestingly, expression of the I212E
mutant strongly decreases H2A ubiquitination below the level
observed for the control siRNA suggesting a dominant-negative
effect. The effect of the F189Q mutant was comparable to wild-
type BMI1 suggesting that mutation of this potential homo-
oligomerization interface involving Phe189 has no significant
effects on BMI1 function (Fig. 4b, Supplementary Fig. 10).
Together, these data demonstrate that point mutations in the
BMI1 UBL domain which disrupt protein–protein interactions or
homo-oligomerization of BMI1 impair the E3 ubiquitin ligase
activity of the PRC1 complex.
BMI1–PHC2 and BMI1–BMI1 interactions regulate BMI1.
To further test the functional importance of the BMI1 UBL
domain interactions we performed clonogenic survival assays
in the human osteosarcoma U2OS cell line. Both BMI1
and PHC2 are expressed at high levels in U2OS cells and have
been found to associate with each other in large nuclear structures
termed polycomb bodies30,48. First, we generated an U2OS cell
line expressing inducible BMI1-targeting short hairpin RNA
(shRNA; see Methods section). Induction of BMI1 shRNA
expression significantly reduced BMI1 protein levels (Fig. 4c)
and resulted in B25% reduction in colony numbers when
compared to the cells expressing non-silencing shRNA
(Fig. 4d, e). We then tested the effect of overexpression of
either wild-type BMI1 or the point mutants (Supplementary
Fig. 11). Overexpression of wild-type BMI1 significantly rescued
the clonogenic potential of U2OS cells (Fig. 4f,g). On the
contrary, overexpression of either R165E/H174E or I212E
mutants did not rescue the clonogenic potential of U2OS cells
expressing BMI1 shRNA. Expression of these two variants of
BMI1 significantly decreased colony numbers when compared to
wild-type BMI1, again supporting that R165E/H174E and I212E
mutants function as dominant negatives (Fig. 4f,g) possibly
through activity of additional PCGF members. Since the
mutations in BMI1 are introduced in the UBL domain, we
expect that both BMI1 variants retain the interaction with
RING1A/B proteins via the N-terminal RING domain. Therefore,
the strong reduction in clonogenic potential of U2OS cells results
from the loss of interaction with PHC2 or from the disruption of
BMI1 homo-oligomerization. Expression of the F189Q mutant
did not fully rescue the clonogenic activity of BMI1 knockdown
cells, suggesting that this mutation also partially impairs BMI1
function; although to a much weaker extent compared to R165E/
H174E or I212E mutants.
Discussion
BMI1 is an essential component of the canonical polycomb
repressive complex 1 (PRC1) that participates in H2A ubiquitin
ligase activity26,27 and in protein–protein interactions
stabilizing the overall architecture of PRC1 (refs 29,30). In this
study, we found that the central domain of BMI1 has an
ubiquitin-like (UBL) fold and plays a dual role in maintaining
protein–protein interactions within PRC1. First, the UBL domain
interacts with the polyhomeotic protein PHC2, a member of the
canonical PRC1. Second, the UBL domain is involved in
homo-oligomerization of BMI1. Employing functional studies
we validated that both of these activities mediated via the UBL
domain are essential for BMI1 function.
Our work supports previous studies demonstrating that the UBL
domain of BMI1 is involved in protein–protein interactions and is
essential for the oncogenic activity of BMI1 (refs 36–38). Here, we
mapped a 24 amino acid fragment of PHC2 that binds to
BMI1 with a submicromolar affinity (KD¼ 398 nM) and 1:1
stoichiometry. We determined the structure of BMI1 in complex
with PHC2 and found that the UBL domain recognizes a
disordered fragment of PHC2 that adopts a hairpin conformation
on binding. Such architecture of the BMI1–PHC2 interaction
involving the UBL domain is conserved among other protein–
protein interactions of polycomb proteins, including the RING1B–
CBX7, RING1B–RYBP and PCGF1–BCOR complexes41,49.
Sequence alignment of BMI1 homologues (PCGF family)
shows that the UBL domain of BMI1 is most similar to MEL18
(PCGF2) with 60% sequence identity, while it differs significantly
from the remaining homologues (Supplementary Fig. 12a,b). To
assess whether the MEL18 UBL domain interacts with PHC2 we
tested the binding of MEL18121-237 fragment with PHC232–61








Sequential (|i-j|¼ 1) 45
Medium-range (|i-j|o5) 11
Long-range PHC2-PHC2 (|i-jZ5) 16
Long-range PHC2–BMI1 (|i-jZ5) 29
Hydrogen bonds 8




Violations (mean and s.d.)
Distance constraints (Å) 0.046±0.114
Dihedral angle constraints () 0.070±0.800
Max. dihedral angle violation () 1.83±3.86
Max. distance constraint violation (Å) 0.88±0.09
Deviations from idealized geometry
Bond lengths (Å) 0.021
Bond angles () 1.8








BMI1, B cell-specific Moloney murine leukemia virus integration site 1; r.m.s.d., root mean square
deviation; PHC2, polyhomeotic homologues.
*Pairwise r.m.s.d. was calculated among 10 refined structures for residues 33–47,127–138,161–231
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using the FP assay. We found that MEL18 binds PHC2 with
slightly reduced affinity (KD¼ 812±9.0 nM) when compared to
BMI1 (Supplementary Fig. 12c). Analysis of the BMI1–PHC2
structure revealed that all BMI1 residues involved in contacts
with PHC2 are identical with MEL18 and strongly suggests very
similar binding mode for MEL18–PHC2. Sequences of the
remaining homologues of BMI1 differ significantly and most
likely they do not interact with PHC proteins.
Our studies identified that BMI1 has a propensity to form
homo-oligomers in solution. We employed analytical ultracen-
trifugation to demonstrate that BMI1 UBL domain undergoes
concentration dependent oligomerization. Analysis of the crystal
packing for the BMI1–PHC2 structure suggested two possible
homo-oligomerization interfaces, one of which harboring Ile212
was validated through mutagenesis studies. Interestingly, our
finding is consistent with the previous observations that full
length RING1B and BMI1 form a heterotetramer in vitro26.
Structure determination of the BMI1–PHC2 complex
represented a significant technical challenge. Previous attempts
at structural studies of the BMI1 UBL domain were hampered by
protein instability41. To design constructs of BMI1 and PHC2
suitable for structural studies we employed 13C-detected NMR
experiments to identify disordered protein fragments39.
Using such an approach we efficiently mapped the minimal
folded fragments of BMI1 and PHC2 involved in this
interaction highlighting the utility of this methodology in
designing constructs for structural biology39. Furthermore,
structure determination of the BMI1–PHC2 complex solely by
either X-ray crystallography or solution NMR was hampered
by additional challenges, such as crystallographic artifacts from
the crystal packing, low protein solubility and high propensity for
aggregation. To resolve these difficulties we used a Rosetta-based
joint refinement method incorporating the crystal structure of the
BMI1 UBL domain and NMR restraints defining UBL–PHC2
contacts. While joint refinement using both methods has
been used before to improve structure accuracy50–53; to our
knowledge, our work represents a unique example where X-ray
crystallography data for a protein–protein complex were not
sufficient for structure determination and NMR restraints were
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Figure 3 | BMI1 UBL forms higher order oligomers in solution. (a) Van Holde-Weischet [G(s)] plots of sedimentation distributions for wild-type BMI1
UBL–PHC21–79 complex showing a concentration dependent increase in particle size in solution. Values of sedimentation coefficients are in parenthesis.
(b) The crystal structure of the BMI1 UBL domain showing two putative homo-oligomerization interfaces identified based on crystal packing. Residues
selected for mutation to block homo-oligomerization are labelled. (c) Binding affinities of BMI1 variants with PHC21-79 determined using fluorescence
polarization experiments titrating FITC–PHC232–61 with wild-type BMI1 UBL or point mutants. Experiments were performed in duplicates, error bars
represent s.d.; KD is reported as the average and s.d. from three independent experiments. (d) Van Holde-Weischet [G(s)] plots of sedimentation
distributions for BMI1 UBL–PHC21–79 complexes at 10 and 50mM comparing the wild-type BMI1 and point mutants F189Q and I212E. (e) Superposition of
1H–15N HSQC spectra for 50mM 15N BMI1 UBL–PHC233–56 complex in the absence (blue) and presence of 100mM unlabelled BMI1 UBL–PHC233–56
complex (red). (f) Superposition of 1H–15N HSQC spectra for 50mM 15N BMI1 UBL–PHC233–56 complex in the absence (blue) and presence of 100mM
unlabelled BMI1 UBL I212E–PHC233–56 complex (red).
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On the basis of our structural studies, we generated and
characterized point mutations in the BMI1 UBL domain, which
disrupt the interaction with polyhomeotic proteins as well as
BMI1 UBL homo-oligomerization. The BMI1 R165E/H174E
double mutant has significantly reduced binding to PHC2 and
the I212E mutant has strongly decreased propensity to
homo-oligomerize. We found that both mutants impair the
activity of PRC1 to ubiquitinate H2A in HeLa cells. Furthermore,
knockdown of BMI1 followed by re-expression of BMI1 R165E/
H174E or I212E mutants strongly decreases the clonogenic
potential of U2OS cells. These findings emphasize that both the
protein–protein interactions and oligomerization mediated
through the UBL domain are necessary for BMI1 function. The
point mutations we characterized provide a potential tool which
might be further explored to dissect functional implications of
disrupting the BMI1 interactions.
Our structural studies established an important role of BMI1 in
coordinating the architecture of the canonical PRC1 complex.
BMI1 is a key structural component of the PRC1 that
simultaneously interacts with RING1A/B and PHC proteins







































































































































Figure 4 | Functional consequences of disrupting BMI1 protein–protein interactions and homo-oligomerization. (a) Analysis of the effect of BMI1
knockdown on Ub-H2A levels in HeLa cells. HeLa cells were transfected with control or BMI1 30 UTR siRNA and followed by immunoblot analysis 48 h post
transfection. (b) Characterization of Ub-H2A levels on overexpression of BMI1 mutants in HeLa cells. HeLa cells transfected with control or BMI1 30 UTR
siRNA for 48 h were transfected with plasmids encoding Flag-tagged full length wild-type BMI1 or three mutants and analysed using immunoblotting after
48 h. (c) Inducible knockdown of BMI1 in U2OS cells using shRNA. U2OS cells carrying control or BMI1 shRNA were treated with doxycycline for 96 h and
cell lysates were analysed for BMI1 expression levels. (d) Quantification of colony numbers from the clonogenic survival assay in panel e demonstrating the
effect of BMI1 knockdown on clonogenic potential of U2OS cells. U2OS cells were plated in triplicates and incubated for 14 days. Error bars represent s.d. of
triplicate wells; *Pr0.05. (e) Representative plates from clonogenic survival assays on BMI1 knockdown in U2OS cells. (f) Quantification of the clonogenic
survival assay in panel g demonstrating the effect of re-expression of BMI1 mutants in U2OS cells expressing BMI1 shRNA. Error bars represent s.d. of
triplicate wells; ***Pr0.001; ****Pr0.0001; ns, not significant. (g) Representative plates from the clonogenic survival assay on BMI1 knockdown and re-
expression of BMI1 mutants in U2OS cells. (h) Proposed architecture of the PRC1 complex.
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bridging the H2A ubiquitin ligase activity of RING1A/B and the
polyhomeotic subunit (Fig. 4h). The interaction of the BMI1 UBL
domain with PHC proteins is essential for the proper assembly of
the PRC1 complex which is needed for ubiquitination of H2A in
cells. To further validate this, we have performed knockdown of
PHC2 and PHC3 and found a very significant loss of H2A
ubiquitination in HeLa cells on simultaneous loss of PHC proteins
(Supplementary Fig. 13). We also found that the BMI1 UBL
domain may represent a motif contributing to the oligomerization
of PRC1. While BMI1 UBL homo-oligomerization is relatively
weak in vitro, the UBL domain may function in concert with SAM
domains, a well-known oligomerization motif in the PHC
subunit (Fig. 4h)54, which is likely involved in PRC1 clustering40.
As previously suggested, PRC1 may regulate gene expression by
compacting chromatin through interactions between distinct PRC1
complexes at either local or distal nucleosomes24,40. Here we
propose a model where the homo-oligomerization properties of
BMI1 enhance the higher order architecture of PRC1 (Fig. 4h).
Emerging studies suggest that BMI1 is a promising target for
the development of anti-cancer therapeutics16. Detailed
characterization of BMI1 protein–protein interactions will
support the design of efficient strategy to reverse the oncogenic
activity of BMI1. The structure of the PHC2–BMI1 complex we
determined here provides the molecular basis to develop small
molecule inhibitors of BMI1 activity and might pave the way
towards novel anti-cancer therapeutics.
Methods
Plasmid construction. cDNA encoding BMI1106–240, BMI1121–235 and MEL18121–237
(ordered from Life Technologies) and full-length PHC2_B (a kind gift from Dr Jeff
Rual, UM Pathology) were subcloned into a modified pET32a vector with a
N-terminal His6-thioredoxin expression tag and PreScission protease cleavage site.
The cDNA encoding the PHC230–64–BMI1121–235 fusion was ordered from Life
Technologies and subcloned into the same vector. The mammalian expression
vectors for pCMV BMI1 and PHC2 constructs were prepared from cDNA using
standard subcloning techniques. The genes for the E. Coli BirA biotin ligase and
Avi–BMI1106–326 were ordered from Genscript and Life Technologies, respectively,
and subcloned into the pCMV vector. Mutant constructs were generated using
QuikChange site-directed mutagenesis protocol (Agilent).
Protein expression and purification. BMI1 UBL domain variants, MEL18 UBL
domain and PHC2–BMI1 fusion were expressed in Codonþ BL21 (DE3) E. coli
cells (Sigma) with an N-terminal His6- thioredoxin tag. Cells were grown in Luria
broth or labelled M9 medium with ampicillin selection. After 16 h induction with
0.5mM IPTG at 18 C cells were resuspended in lysis buffer (50mM tris, pH 7.5 at
25 C, 250mM NaCl, 20mM Imidazole, 0.5mM phenylmethylsulfonyl fluoride
(PMSF), 1mM b-mercaptoethanol (b-ME) and lysed using a cell disrupter. Clarified
lysate was applied to a HisTrap HP (GE Healthcare) and eluted with lysis buffer
containing 0.5M imidazole. To remove the His6- thioredoxin tag, the protein was
cleaved with PreScission protease and BMI1 constructs were further purified using
cation exchange chromatography. Purified protein was buffer exchanged into storage
buffer (100mM bis tris, pH 6.5, 50mM NaCl, 1mM TCEP) using HiPrep Desalting
Column (GE Healthcare). For crystallization, BMI1 was incubated with two-fold
excess of a synthetic PHC233–56 peptide (Genscript) and applied to a Superdex S75
gel filtration column (GE Healthcare) pre-equilibrated with storage buffer.
PHC21–79 was expressed in BL21 (DE3) E. coli cells (Sigma) with an N-terminal
His6- thioredoxin tag. Cells were grown in Luria broth or labelled M9 medium with
ampicillin selection. After 16 h induction with 0.5mM IPTG at 18 C cells were
resuspended in lysis buffer (50mM tris, pH 7.5 at 25 C, 250mM NaCl, 20mM
imidazole, 0.5mM phenylmethylsulfonyl fluoride (PMSF), 1mM b-mercaptoethanol
(b-ME)) and lysed using a cell disrupter. Clarified lysate was applied to a HisTrap
HP (GE Healthcare) and eluted with lysis buffer containing 0.5 M imidazole. The
His6- thioredoxin tag was cleaved with PreScission protease during dialysis against
100-fold excess dialysis buffer (50mM tris, 50mMNaCl, 1mM TCEP at pH 7.5) and
separated from PHC21–79 by nickel affinity. PHC21-79 was further purified by
Superdex S75 gel filtration (GE Healthcare) pre-equilibrated with storage buffer
(50mM phosphate, pH 6.5, 50mM NaCl, 1mM TCEP).
Isothermal titration calorimetry. The measurements were performed using a
VP-ITC titration calorimetric system (MicroCal) at 25 C. BMI1121–235 and
trx-PHC21–79 were dialysed extensively against ITC buffer (50mM phosphate,
pH 6.5, 50mM NaCl, 1mM TCEP). Peptide PHC233–56 (Genscript) was directly
dissolved in ITC buffer. All samples were degassed before measurements. For
measurement of BMI1121–235–PHC21–79 interaction the calorimetric cell,
containing BMI1 (22 mM), was titrated with trx-PHC21–79 (164 mM) injected in
10 ml aliquots. For measurement of BMI1121–235–PHC233–56 interaction the
calorimetric cell, containing BMI1 (9 mM), was titrated with PHC233–56 (100 mM)
injected in 10 ml aliquots. Data were analysed using Origin 7.0 (OriginLab) to
obtain KD and stoichiometry.
Protein NMR experiments. Samples for assignment of 13C15N–BMI1106–240
contained 70mM protein in NMR buffer (50mM bis tris, pH 6.5, 50mM NaCl,
1mM TCEP and 5% D2O). 2D 13C-detected CACO, CBCACO and CANCO
experiments were used for carbon assignment of flexible residues55. Samples for
assignment of PHC21–79 contained 60mM 13C15N–PHC21–79 in a buffer containing
100mM bis tris, pH 6.5, 100mM NaCl, 1mM TCEP and 5% D2O. 2D 13C-detected
CACO, CBCACO and CANCO experiments were used for carbon assignment55.
Mapping the PHC2 motif involved in BMI1 binding was performed for 60mM
13C15N–PHC21–79 mixed with 60mM BMI1 UBL. BMI1 UBL–PHC2 binding
experiments contained 50–100mM 15N-labelled wild-type BMI1121–235 or mutants
and unlabelled PHC233–56. Analysis of peak broadening and aggregation was
performed by titration of 50mM 15N-labelled BMI1121–235 in complex with
PHC233–56 with 50 and 100mM unlabelled BMI1121–235 wild-type or I212E–
PHC233–56 complex. All NMR spectra were acquired at 303K on a 600MHz Bruker
Advance III spectrometer equipped with cryoprobe, running Topspin version 2.1.
Spectra processing and visualization were performed using NMRPipe56 and
Sparky57.
Crystallization and structure determination. Initial crystals were obtained
through sitting drop screening of BMI1121–235–PHC233–56 complex purified using
size exclusion. Crystals were further optimized by hanging-drop vapor diffusion with
equal volumes (1ml) of protein (9mg/ml in 50mM bis tris, pH 6.5, 50mM NaCl,
1mM TCEP) and the precipitant solution (100mMMES, pH 6.5, 50mMMgCl2, 7%
isopropanol, 6% PEG 4000). Crystals formed within 7 days at 4 C. Crystals were
cryoprotected using the precipitant solution containing 20% glycerol and flash frozen
in liquid nitrogen. X-ray diffraction data of crystals were collected at a resolution of
2.5Å at the Advanced Photon Source at LS-CAT beam line 21-ID-F. The data were
indexed, integrated, and scaled using the HKL2000 suite58. The structure was
determined by molecular replacement method with the CCP4 version of MOLREP59
using the polycomb group Ring finger protein complex structure (PDB code 4HPM
B chain) as a search model41. Model building was performed manually using the
program WinCoot60 and the refinement was performed with CCP4 refmac5
(ref. 61). The data statistics are summarized in Table 1.
Structure determination using joint NMR and X-ray refinement.
NMR experiments for structure determination were collected for 200 mM
13C15N–PHC230–64–BMI1121–235 fusion protein in 50mM bis tris, pH 6.5 buffer
with 50mM NaCl, 1mM TCEP and 5% D2O. Backbone assignment was completed
based on a series of triple-resonance experiments including HNCACB, CBCA
(CO)NH, HNCA, HN(CO)CA, HNCO and HN(CA)CO. Methyl side chain
resonances were assigned using 3D 13C-1H-1H HCCH-TOCSY. Distance restraints
were obtained from 3D 15N-separated NOESY-HSQC and 3D 13C-separated
NOESY–HSQC spectra measured with 150ms mixing time. Initial structures were
calculated in CYANA42 based on distance restraints from NOESY spectra and
dihedral angle restraints from TALOSþ (ref. 62). NMR structures of PHC2 were
combined with the X-ray crystal structure of BMI1 UBL domain and the entire
complex was refined using Rosetta43,44,63 constrained by NOE-derived distances
restraints, dihedral angle restraints and BMI1 crystal structure coordinates. BMI1
was restricted during refinement with the exception of loop residues 121–127 and
138–160 which were missing in the crystal structure. These fragments were added
using the loop building protocol64 and were treated as disordered fragments during
Rosetta refinement. Side chains of BMI1 residues 160–178 were unrestricted during
the refinement. Data statistics are summarized in Table 2.
Fluorescence polarization assays. Dissociation constants for binding of PHC2 to
BMI1 UBL domain variants and MEL18 UBL were determined by fluorescence
polarization. Fluorescein-labelled PHC232–61 (Genscript) at 20 nM was titrated with
a range of BMI1 or MEL18 concentrations in the FP buffer (50mM bis tris, pH 7.5,
50mM NaCl, 1mM TCEP, 0.01% BSA, 0.25% tween-20). After 1 h incubation of
the protein–peptide complexes, changes in fluorescence polarization and
anisotropy were measured at 525 nm after excitation at 495 nm using PHERAstar
microplate reader (BMG). Results were used to calculate binding affinity (KD) for
PHC2 with wild-type BMI1, BMI1 mutants, or MEL18 using the Prism 4.0
(GraphPad) program.
Analytical ultracentrifugation. Sedimentation velocity experiments were
performed on a Beckman Optima XL-I at the Center for Analytical
Ultracentrifugation of Macromolecular Assemblies (CAUMA) at the University of
Texas Health Center at San Antonio. Calculations were performed with the
UltraScan software65 at the Texas Advanced Computing Center at the University of
Texas at Austin and at the Bioinformatics Core Facility at the University of Texas
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Health Science Center at San Antonio. Protein samples were prepared by
mixing BMI1 UBL with PHC21–79 followed by size exclusion to purify 1:1
stoichiometric complex. Samples were subsequently concentrated to 10, 50 or
250mM in a 50mM phosphate buffer, pH 6.5 containing 50mM NaCl and 1mM
TCEP. All analytical ultracentrifugation data were collected at 20 C and
spun at 50 k r.p.m., using standard Epon-2 channel centerpieces. All data were first
analysed by two-dimensional spectrum analysis with simultaneous removal of
time-invariant noise66 and then by enhanced van Holde-Weischet analysis67 and
genetic algorithm refinement68 where applicable, followed by Monte Carlo
analysis69.
Cell cultures. Human embryonic kidney-293 (HEK293) (CRL-1573) cell line,
cervical carcinoma cell line (HeLa) (CCL-2) and osteosarcoma cell line U2OS
(HTB-96) were obtained from the American Type Culture Collection and were
cultured either in Dulbecco’s modified Eagle’s medium (for HEK293 and HeLa) or
McCoy’s 5a Medium Modified (for U2OS) supplemented with 10% FBS. For
plasmid transfection, Lipofectamine 2000 (Invitrogen) and, for the siRNA
transfection, Lipofectamine RNAi-max (Invitrogen) were used according to the
manufacturer’s instructions.
Pull-down and co-immunoprecipitation experiments. HEK293 cells were
transfected with BirA, Myc-PHC2_B and Avi-BMI1106–326 constructs using Fugene
6 (Roche) transfection agent. Cells were harvested by centrifugation 48 h after
transfection and lysed through sonication in lysis buffer (50mM HEPES, pH 7.5,
150mM NaCl, 1mM EDTA, 2.5mM EGTA, 1mM NEM, 1mM NaF, 0.1M
Na3VO4, 10% glycerol, 0.1mM b-glycerophospate, 0.01% NP-40) with protease
inhibitor cocktail (Sigma). Lysate was clarified by centrifugation and streptavidin
magnetic beads (Pierce) were added to each sample and incubated at 4 C with
rotation for 16 h. Beads were washed 4 times with wash buffer (20mM tris, pH 8.0,
300mM KCl, 1mM EDTA, 10% glycerol, 0.1% NP-40) with protease inhibitor
cocktail (Sigma) and proteins were boiled in Lammeli buffer. Samples were
analysed by SDS–PAGE and western blotting probed with either Myc antibody
(Cell Signaling, catalog #2276S) or BMI1 antibody (Millipore, catalog #05-637).
10% of the total protein used for pulldown was taken as input control. Uncropped
images of the western blots are shown in Supplementary Fig. 14.
For co-immunoprecipitation experiments HEK293 cells were transfected with
full length Flag-tagged BMI1, R165E/H174E, I212E mutants and Myc-PHC2_B
constructs using lipofectamine 2000 (Invitrogen). After 48 h incubation, cells were
harvested and lysed and processed as described above. Flag-M2 dynabeads (Sigma)
were washed in lysis buffer and added to each sample and incubated at 4 C with
rotation overnight. Beads were washed 3 times with lysis buffer and boiled in 1%
SDS. Samples were mixed with Lammeli buffer, boiled and were analysed by SDS–
PAGE and western blotting with Myc (Cell Signaling), Flag (Sigma, catalog
#F3165), BMI1 (Millipore) and b-Actin antibodies. 10% of the total protein used
for immunoprecipitation was used as an input control.
Lentiviral shRNA-mediated gene knockdown. Control and BMI1 shRNA
expressing U2OS stable transfectant cells were generated using Inducible TRIPZ
Lentiviral shRNA system from Dharmacon. Briefly, various individual clones
targeting different regions of BMI1 (Clone ID; V2THS_48576, V2THS_244779,
V3THS_400015, V3THS_302126) and non-silencing control (shRNA) lentiviral
constructs were obtained, packaged and lentiviral particles were produced as per
manufacturer’s instructions. U2OS cells transduced with individual constructs were
continuously cultured in puromycin to select for cells containing the constructs.
Stable U2OS cells were incubated in Doxycycline (1 mgml l) for 48 h before
assessment for % RFP expression to confirm presence of lentiviral DNA. Based on
knockdown efficiency of BMI1, as determined by RFP expression and quantitative
real time PCR, U2OS cells carrying BMI1 V3THS_400015 clone was selected for
further analysis.
BMI1 knockdown and analysis of ubH2A in HeLa cells. 100,000 HeLa cells were
reverse transfected with 25 nM of BMI1 30UTR siRNA (Dharmacon) for 48 h using
lipofectamine RNAiMax (Invitrogen) as per manufacturer instructions in 6 well
plate. After 48 h of siRNA transfection, medium was replaced and BMI1 wild-type
or mutant constructs were transfected using lipofectamine 2000 (Invitrogen) as per
manufacturer protocol. Cells were incubated for 48 h before washing, trypsinization
and lysis. Equal amounts of whole cell lysate were separated on 10% SDS–PAGE
gels. Blots were probed with primary antibodies (H2Aub(K119), Cell Signaling
Technology, catalog #8240S; BMI1, Millipore; b-Actin, EMD Millipore, catalog
#04-1116; H3, Abcam, catalog #ab1791) overnight at 4 C, washed five times in
TBS plus 0.1% Tween (TBST) and then incubated with the appropriate horseradish
peroxidase-conjugated secondary antibody for 1 h at room temperature.
Membranes were washed five times in TBST and visualized on autoradiography
film after incubating with ECL reagent (ECL Prime, GE Healthcare). Uncropped
images of the western blots are shown in Supplementary Fig. 14.
siRNA mediated PHC2/PHC3 knockdown in HeLa cells. For PHC2 and PHC3
knockdown 100,000 HeLa cells were reverse transfected with either 50 nM of PHC2
and PHC3 siRNAs individually (Dharmacon) or in combination for 96 h using
Lipofectamine RNAiMax as per manufacturer instructions. Equal amounts of
whole cell lysate were separated on 10% SDS–PAGE gels. Blots were probed with
primary antibodies (H2Aub(K119), Cell Signaling Technology; H3 (Abcam);
b-actin, EMD Millipore). PHC2 and PHC3 siRNA mediated knockdown efficiency
was measured by quantitative real time PCR. Uncropped images of the western
blots are shown in Supplementary Fig. 14.
Clonogenic survival assay. Clonogenic survival assays were performed using
techniques described previously70. Briefly, U2OS cells containing control or BMI1
shRNA, were incubated with Doxycycline (1mgml l) for 48 h to induce shRNA
expression. After 48 h incubation, cells were transfected with BMI1 wild-type or
mutant DNA using lipofectamine 2000 (Invitrogen) as per manufacturer protocol
for another 48 h. On completion of 48 h with DNA transfection, cells were washed
with PBS twice, trypsinized, counted and plated at low density (500 cells each well)
in triplicates in 6 well plates and left to grow for 14 days at 37 C. On the 14th day
plates were fixed with methanol-acetic acid, stained with crystal violet, and scored
for colonies containing more than 50 cells to assess the colony-forming ability.
Error bars are from triplicate samples. Differences between control and BMI1
wild-type or mutant samples were analysed by unpaired t-test and P values were
estimated based on this model. Significance was determined based on a significance
level of 0.05. Remaining cells were used for whole cell lysate isolation and
immunoblotting analysis to determine extent of BMI1 knockdown and to confirm
overexpression of BMI1 DNA constructs.
Data availability. The atomic coordinates and structure factors for the BMI1 UBL
domain and the PHC2–BMI1 complex have been deposited in the PDB with
accession codes: 5FR6 and 2NA1. The data that support the findings of this study
are available within the article and its Supplementary Information files, or available
from the corresponding author on request.
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